Early outcomes using alemtuzumab induction in lung transplantation

Interactive Cardiovascular and Thoracic Surgery

Volumn 10, Issue 2, 2010, Pages 190-194

  Van Loenhout, Keetie C J ^a   Groves, Soleyah C ^b   Galazka, Marek ^b   Sherman, Brian ^b   Britt, Edward ^b   Garcia, Jose ^b   Griffith, Bartley ^b   Iacono, Aldo ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Acute rejection; Alemtuzumab; Chronic rejection; Lung function; Pulmonary transplantation

Indexed keywords

ALEMTUZUMAB; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; DIPHENHYDRAMINE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VORICONAZOLE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE COMPARISON; FEMALE; GRAFT INFECTION; GRAFT SURVIVAL; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LUNG FUNCTION; LUNG GRAFT REJECTION; LUNG LAVAGE; LUNG TRANSPLANTATION; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MALE; MYCOSIS; PREMEDICATION; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; VIRUS INFECTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BRONCHITIS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; LENGTH OF STAY; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; MYCOSES; PREDNISONE; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; VIRUS DISEASES;

EID: 75449120538     PISSN: 15699293     EISSN: None     Source Type: Journal    
DOI: 10.1510/icvts.2009.213892     Document Type: Article

References (15)

1. Lin H, Kauffman M, McBride M, Davies D, Rosendale J, Smith C, Edwards E, Daily O, Kirklin J, Shield C, Hunsicker L. Center-specific graft and patient survival rates. J Am Med Assoc 1998;280:1153-1160.
2. Christie J, Edwards L, Aurora P, Dobbels F, Kirk, Rahmel A, Taylor D, Kucheryavaya A, Hertz M. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth Official Adult Lung and Heart/Lung Transplantation Report 2008. J Heart Lung Transplant 2008;27: 957-969.
3. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 2006;81:1361-1367.
4. Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J, Bradley J, Smith K, Waldmann H. Prope tolerance, peri-operative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998;351:1701-1702.
5. Calne R, Moffatt SD, Friend PJ, Jamieson N, Bradley J, Hale G, Firth J, Bradley J, Smith K, Waldmann H. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999;68:1613-1616.
6. Watson CJ, Bradley JA, Friend PJ, Firth J, Taylor CJ, Bradley JR, Smith KG, Thiru S, Jamieson NV, Hale G, Waldmann H, Calne R. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005;5:1347-1353.
7. Vathsala A, Ona ET, Tan S, Suresh S, Lou H, Casasola C, Wong H, Machin D, Chiang G, Danguilan R, Calne R. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005;80:765-774.
8. Ciancio G, Burke G, Gaynor J, Carreno M, Cirocco R, Mathew J, Mattiazzi A, Cordovilla T, Roth D, Kupin W, Rosen A, Esquenazi V, Tzakis A, Miller J. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005;80:457-465.
9. McCurry KR, Iacono A, Zeevi A, Yousem S, Girnita A, Husain S, Zaldonis D, Johnson B, Hattler B, Starzl T. Early outcomes in human lung transplantation with thymoglobulin or Campath-1H for recipient pre-treatment followed by post transplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005;130:528-537.
10. Peleg A, Husain S, Kwak E, Silveira F, Ndirangu M, Tran J, Shutt K, Shapiro R, Thai N, Abu-Elmagd K, McCurry K, Marcos A, Paterson D. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007;44:204-212.
11. Ciancio G, Burke G, Gaynor J, Roth D, Kupin W, Rose A, Cordovilla T, Tueros L, Herrada E, Miller J. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008;22:200-210.
12. Estenne M, Maurer J, Boehler A, Egan J, Frost A, Hertz M, Mallory G, Snell G, Yousem S. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002;21:297-310.
13. Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J 2003;22:1007-1018.
14. Xia M, Hale G, Lifely M, Ferguson M, Campbell D, Packman L, Waldmann H. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293:633-640.
15. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro A, Waldmann H. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983;62:873-882.